MeSH term
Frequency | Condition_Probility | Animals | 21 | 0.0 |
*Antigens, Neoplasm | 11 | 5.0 |
Cell Line | 10 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Humans | 61 | 0.0 |
Kinetics | 3 | 0.0 |
*Tumor Markers, Biological | 13 | 7.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Microscopy, Electron | 3 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 13 | 0.0 |
Adolescent | 3 | 0.0 |
Adult | 16 | 0.0 |
Amyloid/metabolism | 2 | 4.0 |
Disease Progression | 2 | 0.0 |
Immunohistochemistry | 8 | 0.0 |
Middle Aged | 19 | 0.0 |
Research Support, Non-U.S. Gov't | 34 | 0.0 |
Amino Acid Sequence | 7 | 0.0 |
Base Sequence | 9 | 0.0 |
Immunization | 2 | 0.0 |
Mice | 13 | 0.0 |
Mice, Knockout | 3 | 0.0 |
Mice, Nude | 2 | 0.0 |
Molecular Sequence Data | 11 | 0.0 |
Peptide Library | 2 | 1.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Species Specificity | 2 | 0.0 |
Transplantation, Heterologous | 3 | 0.0 |
Female | 24 | 0.0 |
Genotype | 5 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
DNA Primers | 4 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Time Factors | 4 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Protein Binding | 2 | 0.0 |
Organ Culture Techniques | 2 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Blotting, Western | 2 | 0.0 |
DNA Mutational Analysis | 3 | 0.0 |
Male | 19 | 0.0 |
Phenotype | 4 | 0.0 |
Aged | 6 | 0.0 |
Pedigree | 5 | 0.0 |
Rats | 3 | 0.0 |
Recombination, Genetic | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Serine Endopeptidases/*biosynthesis/genetics | 2 | 66.0 |
Stromal Cells/enzymology | 2 | 18.0 |
Substrate Specificity | 2 | 0.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Adenomatous Polyposis Coli/*genetics | 4 | 7.0 |
Genes, APC | 2 | 2.0 |
Germ-Line Mutation | 3 | 0.0 |
English Abstract | 4 | 0.0 |
Reference Values | 2 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Serine Endopeptidases/*metabolism | 2 | 2.0 |
Follow-Up Studies | 4 | 0.0 |
*Genes, APC | 3 | 3.0 |
Sensitivity and Specificity | 2 | 0.0 |
Comparative Study | 2 | 0.0 |
*Serine Endopeptidases | 4 | 11.0 |
COS Cells | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Hamsters | 2 | 0.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Signal Transduction | 2 | 0.0 |
Transfection | 6 | 0.0 |
Epithelium/metabolism | 2 | 0.0 |
*Gelatinases | 2 | 66.0 |
Mutation | 2 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Radioimmunotherapy | 2 | 18.0 |
Cells, Cultured | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Remission Induction | 2 | 0.0 |
Cisplatin/administration & dosage | 2 | 0.0 |
Doxorubicin/administration & dosage | 2 | 1.0 |
Drug Evaluation | 2 | 0.0 |
Fluorouracil/administration & dosage | 2 | 1.0 |
Antibodies, Monoclonal/adverse effects/pharmacokinetics/*therapeutic use | 2 | 20.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Infusions, Intravenous | 2 | 0.0 |
Treatment Outcome | 2 | 0.0 |
